Differing mechanisms of action of angiotensin-converting enzyme inhibition in black and white hypertensive patients

Hypertension

Volumn 26, Issue 1, 1995, Pages 124-130

  Weir, Matthew R ^a   Gray, James M ^b   Paster, Robert ^b   Saunders, Elijah ^b  

^a UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

^b NONE

Author keywords

angiotensin converting enzyme inhibitors; antihypertensive agents; blacks

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; TRANDOLAPRIL; TRANDOLAPRILAT;

ADULT; ARTICLE; CAUCASIAN; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DIASTOLIC BLOOD PRESSURE; DIURESIS; DOUBLE BLIND PROCEDURE; DRUG HYDROLYSIS; ENZYME ACTIVITY; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; NATRIURESIS; NEGRO; PRIORITY JOURNAL; RACE DIFFERENCE; RANDOMIZED CONTROLLED TRIAL;

EID: 0029027577     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.26.1.124     Document Type: Article

References (28)

1. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Racial differences in response to low-dose captopril are abolished by the addition of hydrochlorothiazide. Br J Clin Pharmacol. 1982;14:97s-101s.
2. Saunders E, Weir MR, Kong BW, Hollifield J, Gray J, Vertes V, Sowers J, Zemel MB, Curry C, Schoenberger J, Wright JT, Kirkendall W, Conradi C, Jenkins P, McLean B, Massie B, Berenson G, Flamenbaum W. A comparison of the efficacy and safety of a betablocker, calcium channel blocker, and converting enzyme inhibitor in hypertensive blacks. Arch Intern Med. 1990;150:1707-1713.
3. Materson BJ, Reda DJ, Cushman WC, Massie BM, Freis ED, Kochar MS, Hamburger RJ, Fye C, Lakshman R, Gottdiener J, Ramirez EA, Henderson G. Single drug therapy for hypertension in men: a comparison of six antihypertensive agents with placebo. N Engl J Med. 1993;3281:914-921.
4. Weir MR, Saunders E. Pharmacologics management of systemic hypertension in blacks. Am J Cardiol. 1988;61:46H-52H.
5. Weir MR. Impact of age, race, and obesity on hypertensive mechanisms and therapy. Am J Med. 1991;90(suppl 5A):3S-14S.
6. Weinberger MH. Racial differences in antihypertensive therapy: evidence and implications. Cardiovasc Drugs Ther. 1990;4:379-382.
7. Cesarone MR, De Sanctis MT, Laurora G, Ambrosoli L, Marelli C, Belcaro G. Effects of trandolapril on 24-H ambulatory blood pressure in patients with mild-to-moderate essential hypertension. J Cardiovasc Pharmacol. 1994;23(suppl 4):S65-S72.
8. Due LCN, Brunner HR. Trandolapril in hypertension: overview of a new angiotensin-converting enzyme inhibitor. Am J Cardiol. 1992; 70(suppl 1):27D-34D.
9. Lenfant B, Mouren M, Bryce T, De Lauture D, Strauch G. Trandolapril: pharmacokinetics of single oral doses in healthy male volunteers. J Cardiovasc Pharmacol. 1994;23(suppl 4):S38-S43.
10. Haber E, Koener T, Page LB, Kilman B, Purnode A. Applications of radioimmunoassay for angiotensin I to the physiological measurements of plasma renin activity in normal human subjects. J Clin Endocrinol Metab. 1969;29:1349-1355.
11. Chattoraj SC, Watts NB. Endocrinology. In: Tietz NW, ed. Textbook of Clinical Chemistry. Philadelphia, Pa: WB Saunders; 1986:1075-1076.
12. Lieberman J. Elevation of serum angiotensin-converting-enzyme (ACE) level in sarcoidosis. Am J Med. 1975;59:365-372.
13. Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V). Arch Intern Med. 1993;153:154-183.
14. Final Report on National Black Health Providers Task Force on High Blood Pressure Education and Control. Washington, DC: US Dept of Health and Human Services; 1980.
15. Kannel WB. Role of blood pressure in cardiovascular morbidity and mortality. Prog Cardiovasc Dis. 1974;17:5-24.
16. Finnerty FA. Hypertension is different in blacks. JAMA. 1971;216: 1634-1638.
17. Deubner DC, Tyroler HA, Cassel JC, Hames CG, Becker C. Attributable risk, population attributable risk, and population attributable fraction of death associated with hypertension in a bi-racial population. Circulation. 1975;52:901-908.
18. Cruickshank JK, Beevers DG. Epidemiology of hypertension: blood pressure in blacks and whites. Clin Sci. 1982;62:1-6.
19. Gillum RF. Pathophysiology of hypertension in blacks and whites. Hypertension. 1979;1:468-475.
20. Drayer JI, Weber MA. Monotherapy of essential hypertension with a converting enzyme inhibitor. Hypertension. 1983;5(suppl III):III-108-III-113.
21. Zusman RM. Effects of converting enzyme inhibitors on the reninangiotensin-aldosterone, bradykinin, and arachidonic acid-prostaglandin systems: correlation of chemical structure and biologic activity. Am J Kidney Dis. 1987;10(suppl 1):13-23.
22. Dzau VJ. Significance of the vascular renin-angiotensin pathway. Hypertension. 1986;8:553-561.
23. Dzau VJ. Implications of the local angiotensin production in cardiovascular physiology and pharmacology. Am J Cardiol. 1987;59: 59A-66A.
24. Redgrave JE, Rabinowe SL, Hollenberg NK, Williams GH. Correction of abnormal renal blood flow response to angiotensin II by converting enzyme inhibition. J Clin Invest. 1985;75:1250-1285.
25. Pratt JH, Jones JJ, Miller JZ, Wagner MA, Fineberg NS. Racial differences in aldosterone excretion and plasma aldosterone concentrations in children. N Engl J Med. 1989;321:1152-1157.
26. Fisher NDL, Gleason RE, Moore TJ, Williams GH, Hollenberg NK. Regulation of aldosterone secretion in hypertensive blacks. Hypertension. 1994;23:179-184.
27. Frank GJ, Knapp LE, McLain RW. Overall tolerance and safety of quinapril in clinical trials. Angiology. 1989;40:405-415.
28. Elliot P, Dyer A, Stamler R. The INTERSALT Study: results for 24-hour urinary sodium, by age and sex. J Hum Hypertens. 1989; 3:323-331.